Compliance Program | Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharma to use DSM polymers to develop eye drug delivery tech
Aerie in Europe - EuroTimes
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals Inc (AERI) Q3 2020 Earnings Call Transcript
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Aerie Pharma (AERI) Provides 2020 Company and Guidance Update Associated with COVID-19
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Program
Aerie Pharma: 80% Upside While The Moon Shot Awaits (NASDAQ:AERI) | Seeking Alpha
Aerie Pharmaceuticals to Present at Two Investor Conferences in March | Business Wire
Aerie Pharma: Finding Value In The Ophthalmic Space (NASDAQ:AERI) | Seeking Alpha
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Cantor Initiates Aerie Pharma At Buy: 'Wouldn't Be Surprised If Aerie Became Takeover Candidate'
Aerie Pharma: Significantly Derisked (NASDAQ:AERI) | Seeking Alpha
Durham's Aerie Pharma raises $316.5M, to use funds for eye disease drug development | WRAL TechWire
Aerie Pharmaceuticals - Crunchbase Company Profile & Funding
Eye disease drug firm Aerie Pharma acquires Spanish company for $10M | WRAL TechWire
Ophthalmology Innovation Showcase 1 - Aerie Pharmaceuticals
Aerie-Pharma -
Investor Relations | Aerie Pharmaceuticals, Inc
